Physician profile
Robert Rayson
NPI 1447519905
$1,512.92
in general payments reported to CMS, 2019-2025
14 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $231 · 2021: $174 · 2022: $59.41 · 2023: $253 · 2024: $139 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $408.10 | 2019-2025 | Cardiomems |
| Medtronic, INC. | $360.33 | 2021-2025 | Symplicity G3, Pulseselect |
| Boston Scientific Corporation | $152.36 | 2019-2025 | Neuroblate Robotic Probe Driver |
| Astrazeneca Pharmaceuticals Lp | $99.17 | 2020 | |
| Cardinal Health 200 LLC | $91.80 | 2019 | |
| Philips North America LLC | $79.33 | 2023 | |
| Shockwave Medical, INC | $60.01 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $59.41 | 2022 | |
| Medtronic Vascular, INC. | $58.96 | 2019 | |
| Abiomed | $55.94 | 2024-2025 | Impella |
| Bard Peripheral Vascular, INC. | $39.17 | 2023 | Lutonix Drug Coated Balloon |
| Pfizer INC. | $19.82 | 2019 | |
| Atricure, INC. | $14.40 | 2024 | |
| Terumo Medical Corporation | $14.12 | 2024 | Glidesheath Slender |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Rayson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.